FCGRT and myasthenia gravis: Rozanolixizumab is a humanized IgG4 monoclonal antibody that inhibits FcRn activity to prevent IgG recycling and reduce levels of IgG autoantibodies implicated in the pathogenesis of myasthenia gravis (MG) [9, 10].